WMSA
ARQT icon

Weiss Multi-Strategy Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-170,000
Closed -$549K – 33
2023
Q4 		$549K Buy
170,000
+96,037
+130% +$261K 0.01% 474
2023
Q3 		$393K Sell
73,963
-194,984
-72% -$1.66M 0.01% 493
2023
Q2 		$2.56M Buy
268,947
+141,011
+110% +$1.57M 0.05% 428
2023
Q1 		$1.41M Buy
+127,936
New +$1.85M 0.03% 474

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ARQT Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 170,000 shares — an estimated $549K sold.

Weiss Multi-Strategy Advisers first reported a position in ARQT in Q1 2023 and held it in 4 quarters. The position peaked at $2.56M in Q2 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 170,000 Arcutis Biotherapeutics shares in Q1 2024, an estimated $549K.
  • Weiss Multi-Strategy Advisers first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 4 quarters.
  • Weiss Multi-Strategy Advisers's Arcutis Biotherapeutics position peaked at $2.56M in Q2 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.